← All trials
NCT04678453
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- May 31, 2022
- Completion date
- Sep 30, 2022
- First posted
- Dec 22, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 21
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NKMAX Co., Ltd.Lead sponsor
- Hospital Angeles TijuanaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.